Niche CDMO adds spray drying for highly potent drugs28 Mar 2018
The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.
IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.
The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.
The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.
Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.
“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”
This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.
Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”
FDA success for MedPharm Centre of Excellence
14 Feb 2020
The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.Read more
Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing
12 Feb 2020
Partnership will provide biopharma companies with advanced container closure integrity analysis and testing protocols.Read more
Catalent to manufacture first-in-class mAb targeting solid tumours
11 Feb 2020
ZM008 could have potential benefits for the treatment of prostate cancer.Read more
BD completes clinical trial for its wearable injector
11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.Read more
Innovation awarded at Pharmapack
10 Feb 2020
Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.Read more
2020 - a year for 'big answers' rather than 'big data'
7 Feb 2020
Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.Read more
Recipharm acquisition to make it a top 5 global CDMO?
6 Feb 2020
CEO says the acquisition of Consort Medical will help to create a leading advanced delivery systems company.Read more
New Velesco Pharma clinical manufacturing facility begins operations
5 Feb 2020
The facility will triple the company’s cGMP clinical trial manufacturing capacity.Read more
Colorcon starts No-Tox ink manufacturing at new UK facility
4 Feb 2020
The additional capacity will provide customers with shorter lead times and reduced transportation costs.Read more
Hovione announces key patent grants for its large dose DPI
4 Feb 2020
TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation